Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis

Study limitation reported by the research below: “The meta-analysis pools heterogeneous ROE strategies (e.g., early discontinuation, dose reduction, stop-and-go), which may not be clinically interchangeable.”